Corante

About this Author
DBL%20Hendrix%20small.png College chemistry, 1983

Derek Lowe The 2002 Model

Dbl%20new%20portrait%20B%26W.png After 10 years of blogging. . .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: derekb.lowe@gmail.com Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Emolecules
ChemSpider
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
PubChem
Not Voodoo
DailyMed
Druglib
Clinicaltrials.gov

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
Kilomentor
A New Merck, Reviewed
Liberal Arts Chemistry
Electron Pusher
All Things Metathesis
C&E News Blogs
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
BBSRC/Douglas Kell
ChemBark
Realizations in Biostatistics
Chemjobber
Pharmalot
ChemSpider Blog
Pharmagossip
Med-Chemist
Organic Chem - Education & Industry
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
SimBioSys
The Curious Wavefunction
Natural Product Man
Fragment Literature
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Business|Bytes|Genes|Molecules
Eye on FDA
Chemical Forums
Depth-First
Symyx Blog
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa


Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
FuturePundit
Aetiology
Gene Expression (I)
Gene Expression (II)
Sciencebase
Pharyngula
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
Cosmic Variance
Biology News Net


Medical Blogs
DB's Medical Rants
Science-Based Medicine
GruntDoc
Respectful Insolence
Diabetes Mine


Economics and Business
Marginal Revolution
The Volokh Conspiracy
Knowledge Problem


Politics / Current Events
Virginia Postrel
Instapundit
Belmont Club
Mickey Kaus


Belles Lettres
Uncouth Reflections
Arts and Letters Daily
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« Happy Fourth of July | Main | How Do You Know When to Stop? »

July 6, 2004

Lighting Out for the Frontier

Email This Entry

Posted by Derek

Next week I'll be on vacation, and this week I find myself flogging the chemistry databases. We're looking at a new series of compounds with some interesting activity, and they're easy to make. That's the problem.

They're so easy to make that everyone has made them. That means trouble, because there's so much prior art (and so many potentially interfering claims) that we'd have a difficult time getting a patent position. There are quite a few popular structural classes with this problem: piperazines, indoles, and imidazoles have been trampled flat, for example, and try getting (for example) a claim in some of the benzofuran compound space that Lilly has staked out. Not fun.

So we're looking to change the inner parts of the structure in some non-obvious way and thus stake out a position with some elbow room in it. It's not easy - for one thing, things are to the point that some of the obvious paths to elbow room have already been worn out a little. And you don't want to come up with new ones that are going to take fourteen steps to make, either. That's because it's unclear whether the interesting activity that got us here will persist once we start chopping and rearranging.

Often it doesn't. You feel like a real idiot - even if you aren't - when you spend a lot of time on a series like that and none of the compounds are active. And you feel as if you've wasted our time, because you have. "Fail quickly" is one of the basic mottos of medicinal chemistry.

Comments (3) + TrackBacks (0) | Category: Life in the Drug Labs | Patents and IP


COMMENTS

1. The Novice Chemist on July 7, 2004 2:00 PM writes...


Is "fail quickly" a difficult thing to learn in industry? Grad school is really a perseverance thing and the concept seems odd to me. (Then again, it doesn't. If a synthetic route isn't going to work, you don't want to keep working on it.)

Permalink to Comment

2. qetzal on July 7, 2004 5:28 PM writes...

In my experience, the concept of "fail quickly" is not the tricky bit. It's obvious that there's no point working on something that cannot succeed. The hard part is, how do you know when something won't work?

Presumably, all projects start from a belief that they might work. (OK, maybe that's optimistic, but can we assume that for now? Thanks!)

Over time, one accumulates data, which commonly suggests that the project isn't likely to work after all. But I find that one can almost always come up with alternate ideas, approaches, and explanations why it can still work, even in the face of discouraging results. And I don't just mean in the self-serving, please-don't-kill-my-pet-project sense.

It can be really hard to decide when you've tried all the reasonable avenues, and any residual chance of success is too small to justify further effort. And it doesn't help when we hear the stories of such-and-such a drug that was killed three different times, only to ultimately rise from the ashes, get approved, and make good money.

The art of killing projects is difficult to master, IMHO.

Permalink to Comment

3. qetzal on July 7, 2004 5:45 PM writes...

Novice Chemist's question suggests an interesting blog topic for Derek, if he's reading.

What things are generally not taught to science PhD's, but would be really valuable (especially for people like us who end up in industry, be it big pharma, biotech, whatever)?

Some examples from my experience:

Budgeting & accounting. At least in small biotech, as soon as you make it to a middle mgmt level, you'll likely be asked to prepare budgets for your dept/project, and keep track of your spending. I had no clue how to do that the first time around. And judging from what I've seen in biotech, it's a very common problem.

Leadership & management. How many science PhD's end up having to manage staff? A large fraction. And that applies academics as well as industrial types. When I first had people reporting to me, I had zero training in how to manage and lead their efforts. Even now, almost all my training has been on-the-job experience, supplemented with the occasional half-day course.

And of course, it's not just that these things aren't taught in grad school. Science types rarely take such courses as undergrads either.

Derek, if you read this, maybe you'd like to expand on the theme. Seems like it would make an interesting installment to your "Industry vs Academia" series.

Permalink to Comment


EMAIL THIS ENTRY TO A FRIEND

Email this entry to:

Your email address:

Message (optional):




RELATED ENTRIES
A Last Summer Day Off
The Early FDA
Drug Repurposing
The Smallest Drugs
Life Is Too Short For Some Journal Feeds
A New Look at Phenotypic Screening
Small Molecules - Really, Really Small
InterMune Bought